Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 50, 2020 - Issue 5
3,998
Views
10
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans

, , , , , & show all
Pages 559-569 | Received 13 Jul 2019, Accepted 07 Aug 2019, Published online: 27 Aug 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra & Mehul Kaliya. (2023) Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy 24:18, pages 2187-2198.
Read now
Omar Azzam, Revathy Carnagarin, Leslie Marisol Lugo-Gavidia, Janis Nolde, Vance B. Matthews & Markus P. Schlaich. (2021) Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy 22:16, pages 2095-2103.
Read now

Articles from other publishers (8)

John J. V. McMurray, Scott D. Solomon, J. Paul Lock, Joseph M. Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F. Lewis, Mason W. Freeman & Yuan‐Di C. Halvorsen. (2023) Meta‐analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin . Diabetes, Obesity and Metabolism 26:3, pages 971-979.
Crossref
Najlaa A. Al Thani, Maram Hasan & Huseyin C. Yalcin. (2023) Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors. Journal of Cardiovascular Translational Research 16:5, pages 975-986.
Crossref
Anna Gumieniczek & Anna Berecka-Rycerz. (2023) Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins. Biomedicines 11:8, pages 2127.
Crossref
Sheridan M. Hoy. (2023) Bexagliflozin: First Approval. Drugs 83:5, pages 447-453.
Crossref
Deepak Dalal, Ravi Kant, Kavita Attri, Garima Kapoor, Kandasamy Nagarajan, Rubina Bhutani, Kiran Sharma, Ujjawal Kaushik, Mandeep Yadav & NeetuSingh Jamwal. (2023) A systematic overview of bexagliflozin: A type 2 diabetic drug. Asian Journal of Pharmaceutical Research and Health Care 15:2, pages 109.
Crossref
Yuan‐Di Halvorsen, John Paul Lock, Juan P. Frias, Francisco José Tinahones, Dominik Dahl, Annie L. Conery & Mason W. Freeman. (2022) A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism 25:1, pages 293-301.
Crossref
Xiu Wang, Shi Jin & Weina Hu. (2021) A Role of Glucose Overload in Diabetic Cardiomyopathy in Nonhuman Primates. Journal of Diabetes Research 2021, pages 1-9.
Crossref
Ju-Hyun Kim, Dong Kyun Kim, Won-Gu Choi, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song, Sangkyu Lee & Hye Suk Lee. (2020) In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes. Pharmaceutics 12:9, pages 865.
Crossref